Back to discover

Protein / target

Transcription factor GATA-6

Encoded byGATA6Q92908Homo sapiensSwiss-Prot
UniProt: Q92908Ensembl: ENSG00000141448HGNC: HGNC:4174NCBI Gene: 2627
Degrader-tractable
Druggability
UniProt Ubiquitination
1
Research papers

Protein at a glance

Biological role

Sequence-specific double-stranded DNA binding

Strongest disease association

Atrial septal defect

Via encoding gene GATA6 · Genetic literature evidence · score 0.76

Research activity

Emerging research

1 papers · latest 2020

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Transcriptional activator.

View complete UniProt function annotation

Transcriptional activator (PubMed:19666519, PubMed:22750565, PubMed:22824924, PubMed:27756709). Regulates SEMA3C and PLXNA2 (PubMed:19666519). Involved in gene regulation specifically in the gastric epithelium (PubMed:9315713). May regulate genes that protect epithelial cells from bacterial infection (PubMed:16968778). Involved in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression (By similarity). Binds to BMP response element (BMPRE) DNA sequences within cardiac activating regions (By similarity). In human skin, controls several physiological processes contributing to homeostasis of the upper pilosebaceous unit. Triggers ductal and sebaceous differentiation as well as limits cell proliferation and lipid production to prevent hyperseborrhoea. Mediates the effects of retinoic acid on sebocyte proliferation, differentiation and lipid production. Also contributes to immune regulation of sebocytes and antimicrobial responses by modulating the expression of anti-inflammatory genes such as IL10 and pro-inflammatory genes such as IL6, TLR2, TLR4, and IFNG. Activates TGFB1 signaling which controls the interfollicular epidermis fate (PubMed:33082341)

Subcellular location

Nucleus
Domains and Gene Ontology detail (45)

Gene Ontology

  • Cchromatin
  • Cnucleoplasm
  • Cnucleus
  • Ctranscription regulator complex
  • Fchromatin binding
  • FDNA-binding transcription factor activity
  • FDNA-binding transcription factor activity, RNA polymerase II-specific
  • FDNA-binding transcription factor binding
  • FNFAT protein binding
  • Fprotein kinase binding
  • FRNA polymerase II cis-regulatory region sequence-specific DNA binding
  • Fsequence-specific double-stranded DNA binding

595 aa · 60 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationUniProt · GO
View supporting evidence

Transcriptional regulation

  • ·Transcriptional activator (PubMed:19666519, PubMed:22750565, PubMed:22824924, PubMed:277…
  • ·transcription regulator complex
  • ·DNA-binding transcription factor activity
  • ·DNA-binding transcription factor activity, RNA polymerase II-specific

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene GATA6

Gene-level evidence surfaced through the gene GATA6that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Atrial septal defect
0.62Moderately supported

Genetic literature evidence dominant · Open Targets 0.58

Neurodegenerative Diseases
0.35Preliminary

Pathway evidence dominant · Open Targets 0.54 · no direct causal or clinical evidence

View evidence synthesis (2)
Atrial septal defectModerately supported
0.62
agreement 0.47–0.77
Genetic literature94%Literature6%

Open Targets aggregate 0.58 · 2 independent evidence families

Neurodegenerative DiseasesPreliminary
0.35
agreement 0.13–0.58
Pathway100%

Open Targets aggregate 0.54 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Atrial septal defect0.58
Neurodegenerative Diseases0.54

Tractability

Protein degraders — Emerging

Feasibility evidence (uniprot ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (1)
PR · UniProt Ubiquitination

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2020

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.273 cites

O'Kane GM · Clinical cancer research : an official journal of the American Association for Cancer Research · 2020

Recent

GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.

O'Kane GM · Clinical cancer research : an official journal of the American Association for Cancer Research · 2020

Europe PMC papers linked directly to this protein.